SlideShare ist ein Scribd-Unternehmen logo
1 von 118
SUMMER TRAINING PROJECT GlaxoSmithKline Consumer Health Care Ltd. Presented By: Aanchal Gupta MBA 2-A Roll No. 94972238132
Introduction- Food Processing Industry ,[object Object],[object Object],[object Object],[object Object]
Sectors- Indian Food Processing Industry   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Major Players in Food Processing Industry
Marico India Ltd. ,[object Object],[object Object],[object Object],[object Object]
Britannia Industries Ltd. ,[object Object],[object Object],[object Object],[object Object]
Nestle India Ltd. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dabur India Ltd. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dabur’s Product Categories ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
GLAXOSMITHKLINE  CONSUMER HEALTHCARE LIMITED
Company Profile ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Introduction to GSKCH ,[object Object],[object Object],[object Object],[object Object],[object Object]
Mission ,[object Object]
Historical Background ,[object Object],[object Object],[object Object],[object Object],[object Object]
Contd… ,[object Object],[object Object],[object Object],[object Object]
Business Stations of GSKCH Ltd. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Main Product of GSKCH Ltd. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
About GSKCH Nabha Plant ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Contd… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
5S at Nabha ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Supply Chain Process
Various Departments at GSKCH Ltd. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Finance Department ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SWOT Analysis of Nabha Plant ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Contd… ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
 
 
Title of Project ,[object Object],[object Object],[object Object],[object Object],[object Object]
Objectives of the Study ,[object Object],[object Object]
Research Methodology ,[object Object],[object Object],[object Object],[object Object],[object Object]
Research Methodology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Limitations of Study ,[object Object],[object Object],[object Object],[object Object]
FINANCIAL ANALYSIS  & INTERPRETATION
Types of Financial Analysis   Process of determining financial strengths & weaknesses of firm by establishing strategic relationship between the items of balance sheet, profit & loss account and other operative data
[object Object]
[object Object]
Current Ratio ,[object Object],[object Object],Table 4.1     GSK Nestle Dabur Marico Britannia Current assets 117290.83 8565592 95080.22 565.93 5393415 Current Liabilities 51108 .58 14223846 80764.87 484.46 4132898 Ratio  2.29:1 0.60:1 1.17:1 1.1:1 1.3:1
 
Quick Ratio   ,[object Object],[object Object],Table 4.2   GSK Nestle Dabur Marico Britannia Quick assets  90687.63 3578213 57533.34 292.24 2857084 Current Liabilities (lacs) 51108.58 14223846 80764.87 484.46 4132898 Ratio  1.77:1 0.25:1 0.71:1 0.60:1 0.69:1
 
Absolute Liquid Ratio ,[object Object],[object Object],Table 4.3   GSK Nestle Dabur Marico Britannia Absolute Quick Assets 81979.89 1555863 14842.55 24.96 407978 Current Liabilities (lacs) 51108.58 14223846 80764.87 484.46 4132898 Ratio  1.60:1 0.10:1 0.18:1 0.05:1 0.09:1
 
[object Object],[object Object],[object Object]
Inventory Turnover Ratio ,[object Object],Table 4.4   GSK Nestle Dabur Marico Britannia Net Sales (lacs) 192150.23 51293767 280543.11 1917.17 31122141 Opening Inventory (lacs) 27717.03 4349117 30248.42 218.59 3015309 Closing Inventory (lacs) 26603.2 4987379 37546.88 273.69 2536331 Average (lacs) 27160.115 4668248 33897.65 246.14 2775820 Ratio 7.07 10.98 8.27 7.78 11.21
Graph 4.4
Debtors Turnover Ratio ,[object Object],Table 4.5   GSK Nestle Dabur Marico Britannia Net Sales (lacs) 192150.23 51293767 280543.11 1917.17 31122141 Opening Debtors (lacs) 4325.02 452933 17231.97 41.68 463255 Closing Debtors (lacs) 3135.64 641863 17788.42 61.05 496143 Average (lacs) 3730.33 547398 17510.195 51.365 479699 Ratio 51.51 93.70 16.02 37.32 64.87
Graph 4.5
Creditors Turnover Ratio Creditors Turnover Ratio =  Net Credit Annual Purchases    Average Creditors Table 4.6   GSK Nestle Dabur Marico Britannia Annual Purchase (lacs) 72781.68 24570317 137617.92 1157.03 19103947 Opening Creditors (lacs) 17245.92 5026075 24728.54 186.68 971097 Closing Creditors (lacs) 29063.87 5823233 13612 177.28 896175 Average (lacs) 23154.89 5424654 19170.27 181.98 933636 Ratio 3.14 4.52 7.17 6.35 20.46
Graph 4.6
Working Capital Turnover Ratio ,[object Object],[object Object],Table 4.7   GSK Nestle Dabur Marico Britannia Net Sales (lacs) 192150.23 51293767 280543.11 1917.17 31122141 Net Working Capital (lacs) 66182.25 -5658254 14315.35 81.47 1260517 Ratio 2.90 -9.06 19.59 23.53 24.68
Graph 4.7
[object Object]
Net Profit Ratio   ,[object Object],[object Object],Table 4.8   GSK Nestle Dabur Marico Britannia Net Profit (lacs) 23278.28 6550028 39121.21 142.1 1804001 Net Sales (lacs) 192150.23 51293767 280543.11 1917.17 31122141 Ratio 12.11 12.76 13.94 7.41 5.79
Graph 4.8
Return on Shareholder Fund Return on Shareholder fund =    Net Profit (after interest & tax)  Shareholder’s fund Table 4.9   GSK Nestle Dabur Marico Britannia Net Profit (after interest & tax) 23539.65 6550028 39121.21 142.10 1804001 Shareholders Fund 90509.61 5812650 82338.46 367.68 8245412 Ratio 26.01 112.69 47.51 38.65 21.88
Graph 4.9
Turnover Ratio ,[object Object],[object Object],Table 4.10   GSK Nestle Dabur Marico Britannia Net Sales 192150.23 51293767 280543.11 1917.17 31122141 Total Current Assets 117290.83 8565592 95080.22 565.93 5393415 Ratio 61.04 16.70 33.89 29.52 17.33
Graph 4.10
Earnings Per Share ,[object Object],Table 4.11 GSK Nestle Dabur Marico Britannia Net Profit (lacs) 23539.65 6550028 39121.21 142.10 1804001 No of equity shares (lacs) 420.56 96415.72 8650.76 60.90 23890.36 Earning Per Share Ratio 55.97 67.94 4.52 2.33 75.51
Graph 4.11
[object Object]
Debt Equity Ratio ,[object Object],[object Object],Table 4.12   GSK Nestle Dabur Marico Britannia Outsiders Fund 51108.58 14223846 103523.91 535.76 4384521 Shareholders Fund 90509.61 5812650 82338.46 367.68 8245412 Ratio 0.56 2.45 1.26 1.46 0.53
Graph 4.12
Solvency Ratio ,[object Object],[object Object],Table 4.13   GSK Nestle Dabur Marico Britannia Total Liability to outsider (lacs) 51108.58 14223846 103523.91 535.76 4384521 Total Assets (lacs) 141618.19 20356468 188910.87 903.44 12729354 Ratio 36.08 69.87 54.80 59.30 34.44
Graph 4.13
Proprietary Ratio ,[object Object],[object Object],Table 4.14   GSK Nestle Dabur Marico Britannia Shareholders Fund 90509.61 5812650 82338.46 367.68 8245412 Total Assets 141618.19 20356468 188910.87 903.44 12729354 Ratio 63.91 28.55 43.59 40.70 64.77
Graph 4.14
Fixed Assets to Shareholder funds Ratio Fixed Assets to  =    Fixed Assets (after Dep.) Shareholder funds Ratio  Shareholder funds Table 4.15   GSK Nestle Dabur Marico Britannia Fixed Asset (after depreciation) 23226.15 9758321 36003.11 161.52 2838596 Shareholder Funds 90509.61 5812650 82338.46 367.68 8245412 Ratio 0.26 1.68 0.44 0.44 0.34
Graph 4.15
[object Object]
Trend of Net Sales of GSK   Table 4.16 2005 2006 2007 2008 2009 Net Sales (Lacs) 96684 110787 127847 154175 192150 Trend of Net Sales (%) 100.00 114.59 115.40 120.59 124.63
Trend of Net Sales of Dabur Table 4.17 2005 2006 2007 2008 2009 Net Sales (Lacs) 122623 134279 160043 208340 239616 Trend of Net Sales (%) 100.00 109.51 119.19 130.18 115.01
Trend of Net Sales of Britannia Table 4.18 2005 2006 2007 2008 2009 Net Sales (Lacs) 161540 181790 219930 258410 311220 Trend of Net Sales (%) 100.00 112.54 120.98 117.50 120.44
Trend of Net Sales of Marico Table 4.19 2005 2006 2007 2008 2009 Net Sales (Lacs) 93832 109877 136011 156474 191717 Trend of Net Sales (%) 100.00 117.10 123.78 115.05 122.52
Trend of Net Sales of Nestle Table 4.20 2005 2006 2007 2008 2009 Net Sales (Lacs) 247690 281606 350435 432424 512938 Trend of Net Sales (%) 100.00 113.69 124.44 123.40 118.62
Comparison: Net Sales Growth (%) YOY Table 4.21 2006 2007 2008 2009 GSK 14.59 0.81 5.20 4.04 Dabur 9.51 9.68 10.99 -15.16 Britannia 12.54 8.44 -3.48 2.94 Marico 17.10 6.69 -8.74 7.48 Nestle 13.69 10.75 -1.05 -4.78
Graph 4.21
Trend of Net Profit of GSK   Table 4.22 2005 2006 2007 2008 2009 Net Profit (Lacs) 10715 12693 16268 18833 23278 Trend of Net Profit (%) 100.00 118.46 128.17 115.77 123.60
Trend of Net Profit of Dabur   Table 4.23 2005 2006 2007 2008 2009 Net Profit (Lacs) 15600 21400 28200 33300 39100 Trend of Net Profit (%) 100.00 137.18 131.78 118.09 117.42
Trend of Net Profit of Britannia Table 4.24 2005 2006 2007 2008 2009 Net Profit (Lacs) 14870 14640 10760 19100 18040 Trend of Net Profit (%) 100.00 98.45 73.50 177.51 94.45
Trend of Net Profit of Marico Table:4.25 2005 2006 2007 2008 2009 Net Profit (Lacs) 7010 8690 11290 16910 18870 Trend of Net Profit (%) 100.00 123.97 129.92 149.78 111.59
Trend of Net Profit of Nestle Table 4.26 2005 2006 2007 2008 2009 Net Profit (Lacs) 30957 31510 41381 53408 65500 Trend of Net Profit (%) 100.00 101.79 131.33 129.06 122.64
COMPARISON: Net Profit Growth (%) YOY   Table 4.27 2006 2007 2008 2009 GSK 18.46 9.71 -12.40 7.84 Dabur 37.18 -5.40 -13.69 -0.67 Britannia -1.55 -24.96 104.01 -83.06 Marico 23.97 5.95 19.86 -38.19 Nestle 1.79 29.54 -2.26 -6.42
Graph 4.27
Trend of Earning Per Share of GSK Table 4.28 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 24.84 30.18 38.68 44.78 55.35 Trend of Earning Per Share (%) 100.00 121.50 128.16 115.77 123.60
Trend of Earning Per Share of Dabur Table 4.29 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 2.57 3.20 3.30 3.90 4.50 Trend of Earning Per Share (%) 100.00 124.51 103.13 118.18 115.38
Trend of Earning Per Share of Britannia Table 4.30 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 60.59 59.96 45.06 79.95 75.51 Trend of Earning Per Share (%) 100.00 98.96 75.15 177.43 94.45
Trend of Earning Per Share of Marico Table 4.31 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 1.20 1.50 1.90 2.80 3.10 Trend of Earning Per Share (%) 100.00 125.00 126.67 147.37 110.71
Trend of Earning Per Share of Nestle Table 4.32 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 32.11 32.68 42.92 55.39 67.94 Trend of Earning Per Share (%) 100.00 101.78 131.33 129.05 122.66
Comparison: Earning Per Share Growth    (%) YOY Table 4.33 2006 2007 2008 2009 GSK 21.50 6.67 -12.39 7.83 Dabur 24.51 -21.39 15.06 -2.80 Britannia -1.04 -23.81 102.28 -82.98 Marico 25.00 1.67 20.70 -36.65 Nestle 1.78 29.56 -2.28 -6.40
Graph 4.33
[object Object]
Common Size Statement of GSK Table 4.34 2009 Percentage (%) Currents Assets & loans   Inventories 26603.2 18.79 Sundry Debtors 3135.64 2.21 cash & bank balance 81979.89 57.89 Other current assets 2196.82 1.55 Loans & advances 3375.28 2.38 Total CA (A) 117290.83 82.82 Fixed Assets (B) 23226.15 16.40 Investments ( C ) 0.05 0.00 Deferred Tax Asset (D) 1101.16 0.78 Total Assets (A+B+C+D) 141618.19
Contd... Current Liabilities & provisions   Current liabilities 38095.94 26.90 Provisions 13012.64 9.19 Total Current Liabilities (E) 51108.58 36.09 Shareholders funds   Share Capital (F) 4205.55 2.97 Reserves & Surplus (G) 86304.06 60.94 Deferred tax liability (H) 0 0.00 Total liabilities (E+F+G+H) 141618.19
Common Size Statement of Dabur 2009 Percentage (%) Currents Assets & loans Inventories 37546.88 19.88 Sundry Debtors 17788.42 9.42 cash & bank balance 14842.55 7.86 Loans & advances 24902.37 13.18 Total CA (A) 95080.22 50.33 Fixed Assets (B) 55916.96 29.60 Investments ( C ) 34696.52 18.37 Deferred Tax Asset (D) 2353.09 1.25 Miscellaneous expenditure (E) 864.08 0.46 Total Assets (A+B+C+D+E) 188910.87
Contd . Current Liabilities & provisions 2009 Percentage (%) Liabilities 48165.32 25.50 Provisions 32599.55 17.26 Total Current Liabilities (F) 80764.87 42.75 Shareholders funds Share Capital (G) 8650.76 4.58 Reserves & Surplus (H) 73687.7 39.01 Loan Funds secured (I) 9565.15 5.06 unsecured (J) 13193.89 6.98 Deferred tax liability (K) 3048.5 1.61 Total liabilities (F+G+H+I+J+K) 188910.87
Common Size Statement of Britannia   2009 Percentage (%) Currents Assets & loans Inventories 25363.31 19.93 Sundry Debtors 4961.43 3.90 Cash & bank balance 4079.78 3.21 Other current assets 1370.85 1.08 Loans & advances 18158.78 14.27 Total CA (A) 53934.15 42.37 Fixed Assets (B) 28385.96 22.30 Investments ( C ) 42309.69 33.24 Miscellaneous expenditure (D) 2663.74 2.09 Deferred tax asset (E) 0 0.00 Total Assets (A+B+C+D+E) 127293.54
Contd… Current Liabilities & provisions 2009 Percentage (%) Liabilities 26580.62 20.88 Provisions 14748.36 11.59 Total Current Liabilities (F) 41328.98 32.47 Shareholders funds Share Capital (G) 2389.02 1.88 Reserves & Surplus (H) 80065.1 62.90 Loan Funds Secured (I) 219.72 0.17 Unsecured (J) 2296.51 1.80 Deferred tax liability (K) 994.21 0.78 Total liabilities (F+G+H+I+J+K) 127293.54
Common Size Statement of Marico Table 4.37 2009 Percentage (%) Currents Assets & loans Inventories 33904 29.63 Sundry Debtors 11080 9.68 Cash & bank balance 9219 8.06 Loans & advances 12985 11.35 Total Current Assets (A) 67188 58.72 Fixed Assets (B) 31110 27.19 Investments ( C ) 1211 1.06 Goodwill on consolidation(D) 8503 7.43 Deferred tax asset(E) 6412 5.60 Total Assets (A+B+C+D+E) 114424
Contd... Current Liabilities & provisions 2009 Percentage (%) Liabilities 28027 24.49 Provisions 3551 3.10 Total Current Liabilities (F) 31578 27.60 Shareholders funds Share Capital (G) 6090 5.32 Reserves & Surplus (H) 39259 34.31 Minority interest(I) 0 Loan Funds Secured (J) 10751 9.40 Unsecured (K) 26746 23.37 Total Liabilities (F+G+H+I+J+K) 114424
Common Size Statement of Nestle Table 4.38 2009 Percentage (%) Currents Assets & loans Inventories 49873.8 24.50 Sundry Debtors 6418.63 3.15 cash & bank balance 15558.6 7.64 Loans & advances 13804.9 6.78 Total Current Assets (A) 85655.9 42.08 Fixed Assets (B) 97583.2 47.94 Investments ( C ) 20325.6 9.98 Total Assets (A+B+C) 203565
Contd... Current Liabilities & provisions Current liabilities 58759.1 28.87 Provisions 83479.4 41.01 Total Current Liabilities (D) 142238 69.87 Shareholders funds Share Capital (E) 9641.57 4.74 Reserves & Surplus (F) 48484.9 23.82 Deferred tax liability/(assets) net (G) 3199.72 1.57 Total liabilities (D+E+F+G) 203565
[object Object]
Comparative Balance Sheet of GSK Table 4.39 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 27717.03 26603.2 (1113.83) (4.02) Sundry Debtors 4325.02 3135.64 (1189.38) (27.50) cash & bank balance 47097.69 81979.89 34882.20 74.06 Other current assets 2883.54 2196.82 (686.72) (23.82) Loans & advances 3313.34 3375.28 61.94 1.87 Total CA (A) 85336.62 117290.8 31954.21 37.44 Fixed Assets (B) 22610.83 23226.15 615.32 2.72 Investments ( C ) 0.05 0.05 0.00 Deferred Tax Asset (D) 0 1101.16 1101.16 Total Assets (A+B+C+D) 107947.5 141618.2 33670.69 31.19
Contd... Current Liabilities & provisions 2008 2009 Absolute Change Percentage (%) Current liabilities 25023.53 38095.94 13072.41 52.24 Provisions 6177.67 13012.64 6834.97 110.64 Total Current Liabilities (E) 31201.2 51108.58 19907.38 63.80 Shareholders funds Share Capital (F) 4205.55 4205.55 0.00 0.00 Reserves & Surplus (G) 71882.3 86304.06 14421.76 20.06 Deferred tax liability (H) 658.45 0 (658.45) (100.00) Total liabilities (E+F+G+H) 107947.5 141618.2 33670.69 31.19
Comparative Balance Sheet of Dabur Table 4.40: 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 30248.42 37546.88 7298.46 24.13 Sundry Debtors 17231.97 17788.42 556.45 3.23 Cash & bank balance 7656.81 14842.55 7185.74 93.85 Loans & advances 22253.15 24902.37 2649.22 11.90 Total CA (A) 77390.35 95080.22 17689.87 22.86 Fixed Assets (B) 46525.63 55916.96 9391.33 20.19 Investments ( C ) 20371.63 34696.52 14324.89 70.32 Deferred Tax Asset (D) 2400.73 2353.09 (47.64) (1.98) Miscellaneous expenditure (E) 1395.27 864.08 (531.19) (38.07) Total Assets (A+B+C+D+E) 148083.61 188910.87 40827.26 27.57
Contd... Current Liabilities & provisions Liabilities 45796.70 48165.32 2368.62 5.17 Provisions 27409.97 32599.55 5189.58 18.93 Total Current Liabilities (F) 73206.67 80764.87 7558.20 10.32 Shareholders funds Share Capital (G) 8640.23 8650.76 10.53 0.12 Reserves & Surplus (H) 53592.55 73687.7 20095.15 37.50 Loan Funds Secured (I) 9756.15 9565.15 (191.00) (1.96) Unsecured (J) 160.05 13193.89 13033.84 8143.61 Deferred tax liability (K) 2727.96 3048.5 320.54 11.75 Total liabilities (F+G+H+I+J+K) 148083.61 188910.87 40827.26 27.57
Comparative Balance Sheet of Britannia Table 4.41 2008 2009 Absolute Change Percent age (%) Currents Assets & loans Inventories 30153.09 25363.31 (4789.78) (15.88) Sundry Debtors 4632.55 4961.43 328.88 7.10 Cash & bank balance 4376.64 4079.78 (296.86) (6.78) Other current assets 1319.3 1370.85 Loans & advances 14764.9 18158.78 3393.88 22.99 Total CA (A) 55246.48 53934.15 (1312.33) (2.38) Fixed Assets (B) 25068.07 28385.96 3317.89 13.24 Investments ( C ) 38083 42309.69 4226.69 11.10 Miscellaneous expenditure (D) 2322.58 2663.74 Deferred tax asset (E) 237.59 0 (237.59) (100.00) Total Assets (A+B+C+D+E) 120957.7 127293.5 6335.82 5.24
Contd… Current Liabilities & provisions Liabilities 24701.77 26580.62 1878.85 7.61 Provisions 10065.17 14748.36 4683.19 46.53 Total Current Liabilities (F) 34766.94 41328.98 6562.04 18.87 Shareholders funds Share Capital (G) 2389.02 2389.02 0.00 0.00 Reserves & Surplus (H) 73192.01 80065.1 6873.09 9.39 Loan Funds Secured (I) 193.72 219.72 26.00 13.42 Unsecured (J) 10416.03 2296.51 (8119.52) (77.95) Deferred tax liability (K) 0 994.21 Total liabilities (F+G+H+I+J+K) 120957.7 127293.5 6335.82 5.24
Comparative Balance Sheet of Marico Table 4.42 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 26046 33904 7858.00  30.17  Sundry Debtors 8627 11080 2453.00  28.43  Cash & bank balance 7528 9219 1691.00  22.46  Loans & advances 10609 12985 2376.00  22.40  Total CA (A) 52810 67188 14378.00  27.23  Fixed Assets (B) 25731 31110 5379.00  20.90  Investments ( C ) 1 1211 1210.00  121000.00  Goodwill on consolidation (D) 8424 8503 79.00  0.94  Deferred tax asset (E) 9817 6412 (3405.00) (34.68) Total Assets (A+B+C+D+E) 96783 114424 17641.00  18.23
Contd… Current Liabilities & provisions Liabilities 25596.00  28027 2431.00  9.50  Provisions 3919 3551 (368.00) (9.39) Total Current Liabilities (F) 29515 31578 2063.00  6.99  Shareholders funds Share Capital (G) 6090 6090 0.00  0.00  Reserves & Surplus (H) 25372 39259 13887.00  54.73  Minority interest (I) 12 0 (12.00) (100.00) Loan Funds Secured (J) 13454 10751 (2703.00) (20.09) Unsecured (K) 22340 26746 4406.00  19.72  Total liabilities (F+G+H+I+J+K) 96783 114424 17641.00  18.23
Comparative Balance Sheet of Nestle Table 4.43 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 43491.17 49873.79 6382.62 14.68 Sundry Debtors 4559.33 6418.63 1859.30 40.78 cash & bank balance 19368.93 15558.63 (3810.30) (19.67) Loans & advances 12375.89 13804.87 1428.98 11.55 Total CA (A) 79795.32 85655.92 5860.60 7.34 Fixed Assets (B) 86216.11 97583.21 11367.10 13.18 Investments ( C ) 3489.92 20325.55 16835.63 482.41 Total Assets (A+B+C) 169501.4 203564.7 34063.33 20.10
Contd... Current Liabilities & provisions Current liabilities 50746.71 58759.06 8012.35 15.79 Provisions 67731.57 83479.4 15747.83 23.25 Total Current Liabilities (D) 118478.3 142238.5 23760.18 20.05 Shareholders funds Share Capital (E) 9641.57 9641.57 0.00 0.00 Reserves & Surplus (F) 37693.4 48484.93 10791.53 28.63 Deferred tax liability/(assets) net (G) 3688.1 3199.72 (488.38) (13.24) Total liabilities (D+E+F+G) 169501.4 203564.7 34063.33 20.10
Findings ,[object Object],[object Object],[object Object]
Contd… ,[object Object],[object Object]
Suggestions ,[object Object],[object Object],[object Object]
[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Final group presentation
Final group presentationFinal group presentation
Final group presentationClifford Moon
 
sales and distribution of GSK consumerHealthCare Ltd
sales and distribution of GSK consumerHealthCare Ltdsales and distribution of GSK consumerHealthCare Ltd
sales and distribution of GSK consumerHealthCare LtdAbdulQadir Koitewale
 
Glaxosmithkline portfolio
Glaxosmithkline portfolioGlaxosmithkline portfolio
Glaxosmithkline portfolioVinay Desai
 
Value Chain Analysis of Glaxo Smith Kline
Value Chain Analysis of Glaxo Smith KlineValue Chain Analysis of Glaxo Smith Kline
Value Chain Analysis of Glaxo Smith KlineAbu Jubaer
 
GSK by Taufeeq ahmed
GSK by Taufeeq ahmed  GSK by Taufeeq ahmed
GSK by Taufeeq ahmed Taufeeq Ahmed
 
45415087 gsk-presentation1
45415087 gsk-presentation145415087 gsk-presentation1
45415087 gsk-presentation1adnan424
 
Gsk organizational presentaion
Gsk organizational presentaionGsk organizational presentaion
Gsk organizational presentaionIsmail Khan
 
VRIO analysis of lupin
VRIO analysis of lupin VRIO analysis of lupin
VRIO analysis of lupin Rakesh Bhaskar
 
Janet Morgan, GSK Strategy in action, #makinganimpact15
Janet Morgan, GSK Strategy in action, #makinganimpact15Janet Morgan, GSK Strategy in action, #makinganimpact15
Janet Morgan, GSK Strategy in action, #makinganimpact15CIPR Inside
 
Gsk all-parts-compiled
Gsk all-parts-compiledGsk all-parts-compiled
Gsk all-parts-compiledafsana azmari
 
GlaxoSmithKline Pakistan - Career Development
GlaxoSmithKline Pakistan - Career DevelopmentGlaxoSmithKline Pakistan - Career Development
GlaxoSmithKline Pakistan - Career DevelopmentZeeshan Ali
 
HR Policies in Lupin Limited
HR Policies in Lupin LimitedHR Policies in Lupin Limited
HR Policies in Lupin LimitedManik Kudyar
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentationHarram Aneeqa
 
Glaxo smithkline company pakistan assignment
Glaxo smithkline company pakistan assignmentGlaxo smithkline company pakistan assignment
Glaxo smithkline company pakistan assignmentAli Shah
 
Marketing mix Analysis
Marketing mix AnalysisMarketing mix Analysis
Marketing mix Analysisbappykazi
 

Was ist angesagt? (20)

Gsk m anagement
Gsk m anagementGsk m anagement
Gsk m anagement
 
Final group presentation
Final group presentationFinal group presentation
Final group presentation
 
sales and distribution of GSK consumerHealthCare Ltd
sales and distribution of GSK consumerHealthCare Ltdsales and distribution of GSK consumerHealthCare Ltd
sales and distribution of GSK consumerHealthCare Ltd
 
Glaxosmithkline portfolio
Glaxosmithkline portfolioGlaxosmithkline portfolio
Glaxosmithkline portfolio
 
Value Chain Analysis of Glaxo Smith Kline
Value Chain Analysis of Glaxo Smith KlineValue Chain Analysis of Glaxo Smith Kline
Value Chain Analysis of Glaxo Smith Kline
 
GSK by Taufeeq ahmed
GSK by Taufeeq ahmed  GSK by Taufeeq ahmed
GSK by Taufeeq ahmed
 
45415087 gsk-presentation1
45415087 gsk-presentation145415087 gsk-presentation1
45415087 gsk-presentation1
 
GSK
GSKGSK
GSK
 
Gsk organizational presentaion
Gsk organizational presentaionGsk organizational presentaion
Gsk organizational presentaion
 
merck and co. inc
merck and co. incmerck and co. inc
merck and co. inc
 
VRIO analysis of lupin
VRIO analysis of lupin VRIO analysis of lupin
VRIO analysis of lupin
 
Janet Morgan, GSK Strategy in action, #makinganimpact15
Janet Morgan, GSK Strategy in action, #makinganimpact15Janet Morgan, GSK Strategy in action, #makinganimpact15
Janet Morgan, GSK Strategy in action, #makinganimpact15
 
swot of sun pharma
swot of sun pharmaswot of sun pharma
swot of sun pharma
 
Ranbaxy
RanbaxyRanbaxy
Ranbaxy
 
Gsk all-parts-compiled
Gsk all-parts-compiledGsk all-parts-compiled
Gsk all-parts-compiled
 
GlaxoSmithKline Pakistan - Career Development
GlaxoSmithKline Pakistan - Career DevelopmentGlaxoSmithKline Pakistan - Career Development
GlaxoSmithKline Pakistan - Career Development
 
HR Policies in Lupin Limited
HR Policies in Lupin LimitedHR Policies in Lupin Limited
HR Policies in Lupin Limited
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentation
 
Glaxo smithkline company pakistan assignment
Glaxo smithkline company pakistan assignmentGlaxo smithkline company pakistan assignment
Glaxo smithkline company pakistan assignment
 
Marketing mix Analysis
Marketing mix AnalysisMarketing mix Analysis
Marketing mix Analysis
 

Andere mochten auch

Glaxo-smith-kline-presentation.
 Glaxo-smith-kline-presentation. Glaxo-smith-kline-presentation.
Glaxo-smith-kline-presentation.Ishdeep Singh
 
Epic agro kolkota
Epic agro kolkotaEpic agro kolkota
Epic agro kolkotaJayaraman K
 
Ranbaxy
RanbaxyRanbaxy
Ranbaxyswati
 
Britannia analysis of financial performance
Britannia analysis of financial performanceBritannia analysis of financial performance
Britannia analysis of financial performanceImran Khan
 
Human Resoruce - Training and development (GSK Glaxosmithkline India)
Human Resoruce - Training and development (GSK Glaxosmithkline India)Human Resoruce - Training and development (GSK Glaxosmithkline India)
Human Resoruce - Training and development (GSK Glaxosmithkline India)←ครђเรђ Batra
 
GSK Consumer Healthcare presentation at InnoCosmetics Europe
GSK Consumer Healthcare presentation at InnoCosmetics EuropeGSK Consumer Healthcare presentation at InnoCosmetics Europe
GSK Consumer Healthcare presentation at InnoCosmetics EuropeKGS Global
 
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...sharedserviceslink.com
 
GSK Horlicks Presentation
GSK Horlicks PresentationGSK Horlicks Presentation
GSK Horlicks PresentationShubham Jain
 
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...Maneesh Garg
 
GSK Case Study - Training challenges, approach and tools used
GSK Case Study - Training challenges, approach and tools usedGSK Case Study - Training challenges, approach and tools used
GSK Case Study - Training challenges, approach and tools usedAssima
 
GlaxoSmithkline
GlaxoSmithklineGlaxoSmithkline
GlaxoSmithklineruchi202
 
marico limited
marico limitedmarico limited
marico limitedReeti Pal
 
Summer internship project report
Summer internship project reportSummer internship project report
Summer internship project reportManish Singh
 

Andere mochten auch (18)

The MPS at GSK
The MPS at GSKThe MPS at GSK
The MPS at GSK
 
GlaxoSmithKline
GlaxoSmithKlineGlaxoSmithKline
GlaxoSmithKline
 
Glaxo-smith-kline-presentation.
 Glaxo-smith-kline-presentation. Glaxo-smith-kline-presentation.
Glaxo-smith-kline-presentation.
 
Britannia ppt
Britannia pptBritannia ppt
Britannia ppt
 
Epic agro kolkota
Epic agro kolkotaEpic agro kolkota
Epic agro kolkota
 
GSK at a Glance
GSK at a GlanceGSK at a Glance
GSK at a Glance
 
Ranbaxy
RanbaxyRanbaxy
Ranbaxy
 
Britannia analysis of financial performance
Britannia analysis of financial performanceBritannia analysis of financial performance
Britannia analysis of financial performance
 
Marico
MaricoMarico
Marico
 
Human Resoruce - Training and development (GSK Glaxosmithkline India)
Human Resoruce - Training and development (GSK Glaxosmithkline India)Human Resoruce - Training and development (GSK Glaxosmithkline India)
Human Resoruce - Training and development (GSK Glaxosmithkline India)
 
GSK Consumer Healthcare presentation at InnoCosmetics Europe
GSK Consumer Healthcare presentation at InnoCosmetics EuropeGSK Consumer Healthcare presentation at InnoCosmetics Europe
GSK Consumer Healthcare presentation at InnoCosmetics Europe
 
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...
Supply chain finance models Part 1: bank-agnostic models, bank-funded and man...
 
GSK Horlicks Presentation
GSK Horlicks PresentationGSK Horlicks Presentation
GSK Horlicks Presentation
 
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
 
GSK Case Study - Training challenges, approach and tools used
GSK Case Study - Training challenges, approach and tools usedGSK Case Study - Training challenges, approach and tools used
GSK Case Study - Training challenges, approach and tools used
 
GlaxoSmithkline
GlaxoSmithklineGlaxoSmithkline
GlaxoSmithkline
 
marico limited
marico limitedmarico limited
marico limited
 
Summer internship project report
Summer internship project reportSummer internship project report
Summer internship project report
 

Ähnlich wie Summer Training Presentation

Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitch
Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitchLifespan Pharma Inc-Extend Lifespan Naturally-business plan pitch
Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitchMorris Johnson
 
Food industry analysis
Food industry analysisFood industry analysis
Food industry analysisAshray Patil
 
A project report on dabur
A project report on daburA project report on dabur
A project report on daburSatnam Wadwal
 
Summer internship project - Retailer satisfaction level regarding dairy produ...
Summer internship project - Retailer satisfaction level regarding dairy produ...Summer internship project - Retailer satisfaction level regarding dairy produ...
Summer internship project - Retailer satisfaction level regarding dairy produ...Harshit Soni
 
dokumen.tips_performance-appraisal-of-britania.pdf
dokumen.tips_performance-appraisal-of-britania.pdfdokumen.tips_performance-appraisal-of-britania.pdf
dokumen.tips_performance-appraisal-of-britania.pdfDarpanTaneja1
 
Research insight on Britannia industries
Research insight on Britannia industriesResearch insight on Britannia industries
Research insight on Britannia industriesRupsaChakraborty7
 
Nestle India - Company Profile
Nestle India - Company ProfileNestle India - Company Profile
Nestle India - Company ProfileSudeep Singh
 
Nutritious biscuit : Ragi Biscuits
Nutritious biscuit : Ragi BiscuitsNutritious biscuit : Ragi Biscuits
Nutritious biscuit : Ragi BiscuitsMD SALMAN ANJUM
 
Inception of an Organic Food Company - Horizon 'Spot The Case' Final Round
Inception of an Organic Food Company - Horizon 'Spot The Case' Final RoundInception of an Organic Food Company - Horizon 'Spot The Case' Final Round
Inception of an Organic Food Company - Horizon 'Spot The Case' Final RoundMd Abrar Jahin
 
Contemporary- Indian dairy industry
Contemporary- Indian dairy industryContemporary- Indian dairy industry
Contemporary- Indian dairy industryastha inani
 
A project report on consumer perception towards nandini milk
A project report on  consumer perception towards nandini milkA project report on  consumer perception towards nandini milk
A project report on consumer perception towards nandini milkradhikanaiduji
 
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...Sukkur IBA University
 
Ebm internship report
Ebm internship reportEbm internship report
Ebm internship reportHamid Hussain
 

Ähnlich wie Summer Training Presentation (20)

Fmcg industry in india
Fmcg industry in indiaFmcg industry in india
Fmcg industry in india
 
Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitch
Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitchLifespan Pharma Inc-Extend Lifespan Naturally-business plan pitch
Lifespan Pharma Inc-Extend Lifespan Naturally-business plan pitch
 
Amul
AmulAmul
Amul
 
Food industry analysis
Food industry analysisFood industry analysis
Food industry analysis
 
A project report on dabur
A project report on daburA project report on dabur
A project report on dabur
 
Summer internship project - Retailer satisfaction level regarding dairy produ...
Summer internship project - Retailer satisfaction level regarding dairy produ...Summer internship project - Retailer satisfaction level regarding dairy produ...
Summer internship project - Retailer satisfaction level regarding dairy produ...
 
dokumen.tips_performance-appraisal-of-britania.pdf
dokumen.tips_performance-appraisal-of-britania.pdfdokumen.tips_performance-appraisal-of-britania.pdf
dokumen.tips_performance-appraisal-of-britania.pdf
 
Research insight on Britannia industries
Research insight on Britannia industriesResearch insight on Britannia industries
Research insight on Britannia industries
 
National Foods - Introduction To ERP Systems
National Foods - Introduction To ERP SystemsNational Foods - Introduction To ERP Systems
National Foods - Introduction To ERP Systems
 
Nestle India - Company Profile
Nestle India - Company ProfileNestle India - Company Profile
Nestle India - Company Profile
 
Nutritious biscuit : Ragi Biscuits
Nutritious biscuit : Ragi BiscuitsNutritious biscuit : Ragi Biscuits
Nutritious biscuit : Ragi Biscuits
 
Alkem report safi
Alkem report safiAlkem report safi
Alkem report safi
 
Mgt314 final report
Mgt314 final reportMgt314 final report
Mgt314 final report
 
Sumul
SumulSumul
Sumul
 
Sumul
SumulSumul
Sumul
 
Inception of an Organic Food Company - Horizon 'Spot The Case' Final Round
Inception of an Organic Food Company - Horizon 'Spot The Case' Final RoundInception of an Organic Food Company - Horizon 'Spot The Case' Final Round
Inception of an Organic Food Company - Horizon 'Spot The Case' Final Round
 
Contemporary- Indian dairy industry
Contemporary- Indian dairy industryContemporary- Indian dairy industry
Contemporary- Indian dairy industry
 
A project report on consumer perception towards nandini milk
A project report on  consumer perception towards nandini milkA project report on  consumer perception towards nandini milk
A project report on consumer perception towards nandini milk
 
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...
Report of company visit, bba agribusiness (7 th semester), group 2 (abdullah,...
 
Ebm internship report
Ebm internship reportEbm internship report
Ebm internship report
 

Mehr von Aanchal09

Important News (November - Second Week)
Important News (November -  Second Week)Important News (November -  Second Week)
Important News (November - Second Week)Aanchal09
 
Important News (October - Third Week)
Important News (October - Third Week)Important News (October - Third Week)
Important News (October - Third Week)Aanchal09
 
Important News (October - Second Week)
Important News (October - Second Week)Important News (October - Second Week)
Important News (October - Second Week)Aanchal09
 
Important News (October - First Week)
Important News (October - First Week)Important News (October - First Week)
Important News (October - First Week)Aanchal09
 
Important news 6
Important news 6Important news 6
Important news 6Aanchal09
 
Important News (September - Fourth Week)
Important News (September - Fourth Week)Important News (September - Fourth Week)
Important News (September - Fourth Week)Aanchal09
 
Important News (August- last Week)
Important News (August- last Week)Important News (August- last Week)
Important News (August- last Week)Aanchal09
 

Mehr von Aanchal09 (7)

Important News (November - Second Week)
Important News (November -  Second Week)Important News (November -  Second Week)
Important News (November - Second Week)
 
Important News (October - Third Week)
Important News (October - Third Week)Important News (October - Third Week)
Important News (October - Third Week)
 
Important News (October - Second Week)
Important News (October - Second Week)Important News (October - Second Week)
Important News (October - Second Week)
 
Important News (October - First Week)
Important News (October - First Week)Important News (October - First Week)
Important News (October - First Week)
 
Important news 6
Important news 6Important news 6
Important news 6
 
Important News (September - Fourth Week)
Important News (September - Fourth Week)Important News (September - Fourth Week)
Important News (September - Fourth Week)
 
Important News (August- last Week)
Important News (August- last Week)Important News (August- last Week)
Important News (August- last Week)
 

Summer Training Presentation

  • 1. SUMMER TRAINING PROJECT GlaxoSmithKline Consumer Health Care Ltd. Presented By: Aanchal Gupta MBA 2-A Roll No. 94972238132
  • 2.
  • 3.
  • 4. Major Players in Food Processing Industry
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.  
  • 28.  
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34. FINANCIAL ANALYSIS & INTERPRETATION
  • 35. Types of Financial Analysis Process of determining financial strengths & weaknesses of firm by establishing strategic relationship between the items of balance sheet, profit & loss account and other operative data
  • 36.
  • 37.
  • 38.
  • 39.  
  • 40.
  • 41.  
  • 42.
  • 43.  
  • 44.
  • 45.
  • 47.
  • 49. Creditors Turnover Ratio Creditors Turnover Ratio = Net Credit Annual Purchases Average Creditors Table 4.6   GSK Nestle Dabur Marico Britannia Annual Purchase (lacs) 72781.68 24570317 137617.92 1157.03 19103947 Opening Creditors (lacs) 17245.92 5026075 24728.54 186.68 971097 Closing Creditors (lacs) 29063.87 5823233 13612 177.28 896175 Average (lacs) 23154.89 5424654 19170.27 181.98 933636 Ratio 3.14 4.52 7.17 6.35 20.46
  • 51.
  • 53.
  • 54.
  • 56. Return on Shareholder Fund Return on Shareholder fund = Net Profit (after interest & tax) Shareholder’s fund Table 4.9   GSK Nestle Dabur Marico Britannia Net Profit (after interest & tax) 23539.65 6550028 39121.21 142.10 1804001 Shareholders Fund 90509.61 5812650 82338.46 367.68 8245412 Ratio 26.01 112.69 47.51 38.65 21.88
  • 58.
  • 60.
  • 62.
  • 63.
  • 65.
  • 67.
  • 69. Fixed Assets to Shareholder funds Ratio Fixed Assets to = Fixed Assets (after Dep.) Shareholder funds Ratio Shareholder funds Table 4.15   GSK Nestle Dabur Marico Britannia Fixed Asset (after depreciation) 23226.15 9758321 36003.11 161.52 2838596 Shareholder Funds 90509.61 5812650 82338.46 367.68 8245412 Ratio 0.26 1.68 0.44 0.44 0.34
  • 71.
  • 72. Trend of Net Sales of GSK Table 4.16 2005 2006 2007 2008 2009 Net Sales (Lacs) 96684 110787 127847 154175 192150 Trend of Net Sales (%) 100.00 114.59 115.40 120.59 124.63
  • 73. Trend of Net Sales of Dabur Table 4.17 2005 2006 2007 2008 2009 Net Sales (Lacs) 122623 134279 160043 208340 239616 Trend of Net Sales (%) 100.00 109.51 119.19 130.18 115.01
  • 74. Trend of Net Sales of Britannia Table 4.18 2005 2006 2007 2008 2009 Net Sales (Lacs) 161540 181790 219930 258410 311220 Trend of Net Sales (%) 100.00 112.54 120.98 117.50 120.44
  • 75. Trend of Net Sales of Marico Table 4.19 2005 2006 2007 2008 2009 Net Sales (Lacs) 93832 109877 136011 156474 191717 Trend of Net Sales (%) 100.00 117.10 123.78 115.05 122.52
  • 76. Trend of Net Sales of Nestle Table 4.20 2005 2006 2007 2008 2009 Net Sales (Lacs) 247690 281606 350435 432424 512938 Trend of Net Sales (%) 100.00 113.69 124.44 123.40 118.62
  • 77. Comparison: Net Sales Growth (%) YOY Table 4.21 2006 2007 2008 2009 GSK 14.59 0.81 5.20 4.04 Dabur 9.51 9.68 10.99 -15.16 Britannia 12.54 8.44 -3.48 2.94 Marico 17.10 6.69 -8.74 7.48 Nestle 13.69 10.75 -1.05 -4.78
  • 79. Trend of Net Profit of GSK Table 4.22 2005 2006 2007 2008 2009 Net Profit (Lacs) 10715 12693 16268 18833 23278 Trend of Net Profit (%) 100.00 118.46 128.17 115.77 123.60
  • 80. Trend of Net Profit of Dabur Table 4.23 2005 2006 2007 2008 2009 Net Profit (Lacs) 15600 21400 28200 33300 39100 Trend of Net Profit (%) 100.00 137.18 131.78 118.09 117.42
  • 81. Trend of Net Profit of Britannia Table 4.24 2005 2006 2007 2008 2009 Net Profit (Lacs) 14870 14640 10760 19100 18040 Trend of Net Profit (%) 100.00 98.45 73.50 177.51 94.45
  • 82. Trend of Net Profit of Marico Table:4.25 2005 2006 2007 2008 2009 Net Profit (Lacs) 7010 8690 11290 16910 18870 Trend of Net Profit (%) 100.00 123.97 129.92 149.78 111.59
  • 83. Trend of Net Profit of Nestle Table 4.26 2005 2006 2007 2008 2009 Net Profit (Lacs) 30957 31510 41381 53408 65500 Trend of Net Profit (%) 100.00 101.79 131.33 129.06 122.64
  • 84. COMPARISON: Net Profit Growth (%) YOY Table 4.27 2006 2007 2008 2009 GSK 18.46 9.71 -12.40 7.84 Dabur 37.18 -5.40 -13.69 -0.67 Britannia -1.55 -24.96 104.01 -83.06 Marico 23.97 5.95 19.86 -38.19 Nestle 1.79 29.54 -2.26 -6.42
  • 86. Trend of Earning Per Share of GSK Table 4.28 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 24.84 30.18 38.68 44.78 55.35 Trend of Earning Per Share (%) 100.00 121.50 128.16 115.77 123.60
  • 87. Trend of Earning Per Share of Dabur Table 4.29 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 2.57 3.20 3.30 3.90 4.50 Trend of Earning Per Share (%) 100.00 124.51 103.13 118.18 115.38
  • 88. Trend of Earning Per Share of Britannia Table 4.30 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 60.59 59.96 45.06 79.95 75.51 Trend of Earning Per Share (%) 100.00 98.96 75.15 177.43 94.45
  • 89. Trend of Earning Per Share of Marico Table 4.31 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 1.20 1.50 1.90 2.80 3.10 Trend of Earning Per Share (%) 100.00 125.00 126.67 147.37 110.71
  • 90. Trend of Earning Per Share of Nestle Table 4.32 2005 2006 2007 2008 2009 Earning Per Share (Lacs) 32.11 32.68 42.92 55.39 67.94 Trend of Earning Per Share (%) 100.00 101.78 131.33 129.05 122.66
  • 91. Comparison: Earning Per Share Growth (%) YOY Table 4.33 2006 2007 2008 2009 GSK 21.50 6.67 -12.39 7.83 Dabur 24.51 -21.39 15.06 -2.80 Britannia -1.04 -23.81 102.28 -82.98 Marico 25.00 1.67 20.70 -36.65 Nestle 1.78 29.56 -2.28 -6.40
  • 93.
  • 94. Common Size Statement of GSK Table 4.34 2009 Percentage (%) Currents Assets & loans   Inventories 26603.2 18.79 Sundry Debtors 3135.64 2.21 cash & bank balance 81979.89 57.89 Other current assets 2196.82 1.55 Loans & advances 3375.28 2.38 Total CA (A) 117290.83 82.82 Fixed Assets (B) 23226.15 16.40 Investments ( C ) 0.05 0.00 Deferred Tax Asset (D) 1101.16 0.78 Total Assets (A+B+C+D) 141618.19
  • 95. Contd... Current Liabilities & provisions   Current liabilities 38095.94 26.90 Provisions 13012.64 9.19 Total Current Liabilities (E) 51108.58 36.09 Shareholders funds   Share Capital (F) 4205.55 2.97 Reserves & Surplus (G) 86304.06 60.94 Deferred tax liability (H) 0 0.00 Total liabilities (E+F+G+H) 141618.19
  • 96. Common Size Statement of Dabur 2009 Percentage (%) Currents Assets & loans Inventories 37546.88 19.88 Sundry Debtors 17788.42 9.42 cash & bank balance 14842.55 7.86 Loans & advances 24902.37 13.18 Total CA (A) 95080.22 50.33 Fixed Assets (B) 55916.96 29.60 Investments ( C ) 34696.52 18.37 Deferred Tax Asset (D) 2353.09 1.25 Miscellaneous expenditure (E) 864.08 0.46 Total Assets (A+B+C+D+E) 188910.87
  • 97. Contd . Current Liabilities & provisions 2009 Percentage (%) Liabilities 48165.32 25.50 Provisions 32599.55 17.26 Total Current Liabilities (F) 80764.87 42.75 Shareholders funds Share Capital (G) 8650.76 4.58 Reserves & Surplus (H) 73687.7 39.01 Loan Funds secured (I) 9565.15 5.06 unsecured (J) 13193.89 6.98 Deferred tax liability (K) 3048.5 1.61 Total liabilities (F+G+H+I+J+K) 188910.87
  • 98. Common Size Statement of Britannia   2009 Percentage (%) Currents Assets & loans Inventories 25363.31 19.93 Sundry Debtors 4961.43 3.90 Cash & bank balance 4079.78 3.21 Other current assets 1370.85 1.08 Loans & advances 18158.78 14.27 Total CA (A) 53934.15 42.37 Fixed Assets (B) 28385.96 22.30 Investments ( C ) 42309.69 33.24 Miscellaneous expenditure (D) 2663.74 2.09 Deferred tax asset (E) 0 0.00 Total Assets (A+B+C+D+E) 127293.54
  • 99. Contd… Current Liabilities & provisions 2009 Percentage (%) Liabilities 26580.62 20.88 Provisions 14748.36 11.59 Total Current Liabilities (F) 41328.98 32.47 Shareholders funds Share Capital (G) 2389.02 1.88 Reserves & Surplus (H) 80065.1 62.90 Loan Funds Secured (I) 219.72 0.17 Unsecured (J) 2296.51 1.80 Deferred tax liability (K) 994.21 0.78 Total liabilities (F+G+H+I+J+K) 127293.54
  • 100. Common Size Statement of Marico Table 4.37 2009 Percentage (%) Currents Assets & loans Inventories 33904 29.63 Sundry Debtors 11080 9.68 Cash & bank balance 9219 8.06 Loans & advances 12985 11.35 Total Current Assets (A) 67188 58.72 Fixed Assets (B) 31110 27.19 Investments ( C ) 1211 1.06 Goodwill on consolidation(D) 8503 7.43 Deferred tax asset(E) 6412 5.60 Total Assets (A+B+C+D+E) 114424
  • 101. Contd... Current Liabilities & provisions 2009 Percentage (%) Liabilities 28027 24.49 Provisions 3551 3.10 Total Current Liabilities (F) 31578 27.60 Shareholders funds Share Capital (G) 6090 5.32 Reserves & Surplus (H) 39259 34.31 Minority interest(I) 0 Loan Funds Secured (J) 10751 9.40 Unsecured (K) 26746 23.37 Total Liabilities (F+G+H+I+J+K) 114424
  • 102. Common Size Statement of Nestle Table 4.38 2009 Percentage (%) Currents Assets & loans Inventories 49873.8 24.50 Sundry Debtors 6418.63 3.15 cash & bank balance 15558.6 7.64 Loans & advances 13804.9 6.78 Total Current Assets (A) 85655.9 42.08 Fixed Assets (B) 97583.2 47.94 Investments ( C ) 20325.6 9.98 Total Assets (A+B+C) 203565
  • 103. Contd... Current Liabilities & provisions Current liabilities 58759.1 28.87 Provisions 83479.4 41.01 Total Current Liabilities (D) 142238 69.87 Shareholders funds Share Capital (E) 9641.57 4.74 Reserves & Surplus (F) 48484.9 23.82 Deferred tax liability/(assets) net (G) 3199.72 1.57 Total liabilities (D+E+F+G) 203565
  • 104.
  • 105. Comparative Balance Sheet of GSK Table 4.39 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 27717.03 26603.2 (1113.83) (4.02) Sundry Debtors 4325.02 3135.64 (1189.38) (27.50) cash & bank balance 47097.69 81979.89 34882.20 74.06 Other current assets 2883.54 2196.82 (686.72) (23.82) Loans & advances 3313.34 3375.28 61.94 1.87 Total CA (A) 85336.62 117290.8 31954.21 37.44 Fixed Assets (B) 22610.83 23226.15 615.32 2.72 Investments ( C ) 0.05 0.05 0.00 Deferred Tax Asset (D) 0 1101.16 1101.16 Total Assets (A+B+C+D) 107947.5 141618.2 33670.69 31.19
  • 106. Contd... Current Liabilities & provisions 2008 2009 Absolute Change Percentage (%) Current liabilities 25023.53 38095.94 13072.41 52.24 Provisions 6177.67 13012.64 6834.97 110.64 Total Current Liabilities (E) 31201.2 51108.58 19907.38 63.80 Shareholders funds Share Capital (F) 4205.55 4205.55 0.00 0.00 Reserves & Surplus (G) 71882.3 86304.06 14421.76 20.06 Deferred tax liability (H) 658.45 0 (658.45) (100.00) Total liabilities (E+F+G+H) 107947.5 141618.2 33670.69 31.19
  • 107. Comparative Balance Sheet of Dabur Table 4.40: 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 30248.42 37546.88 7298.46 24.13 Sundry Debtors 17231.97 17788.42 556.45 3.23 Cash & bank balance 7656.81 14842.55 7185.74 93.85 Loans & advances 22253.15 24902.37 2649.22 11.90 Total CA (A) 77390.35 95080.22 17689.87 22.86 Fixed Assets (B) 46525.63 55916.96 9391.33 20.19 Investments ( C ) 20371.63 34696.52 14324.89 70.32 Deferred Tax Asset (D) 2400.73 2353.09 (47.64) (1.98) Miscellaneous expenditure (E) 1395.27 864.08 (531.19) (38.07) Total Assets (A+B+C+D+E) 148083.61 188910.87 40827.26 27.57
  • 108. Contd... Current Liabilities & provisions Liabilities 45796.70 48165.32 2368.62 5.17 Provisions 27409.97 32599.55 5189.58 18.93 Total Current Liabilities (F) 73206.67 80764.87 7558.20 10.32 Shareholders funds Share Capital (G) 8640.23 8650.76 10.53 0.12 Reserves & Surplus (H) 53592.55 73687.7 20095.15 37.50 Loan Funds Secured (I) 9756.15 9565.15 (191.00) (1.96) Unsecured (J) 160.05 13193.89 13033.84 8143.61 Deferred tax liability (K) 2727.96 3048.5 320.54 11.75 Total liabilities (F+G+H+I+J+K) 148083.61 188910.87 40827.26 27.57
  • 109. Comparative Balance Sheet of Britannia Table 4.41 2008 2009 Absolute Change Percent age (%) Currents Assets & loans Inventories 30153.09 25363.31 (4789.78) (15.88) Sundry Debtors 4632.55 4961.43 328.88 7.10 Cash & bank balance 4376.64 4079.78 (296.86) (6.78) Other current assets 1319.3 1370.85 Loans & advances 14764.9 18158.78 3393.88 22.99 Total CA (A) 55246.48 53934.15 (1312.33) (2.38) Fixed Assets (B) 25068.07 28385.96 3317.89 13.24 Investments ( C ) 38083 42309.69 4226.69 11.10 Miscellaneous expenditure (D) 2322.58 2663.74 Deferred tax asset (E) 237.59 0 (237.59) (100.00) Total Assets (A+B+C+D+E) 120957.7 127293.5 6335.82 5.24
  • 110. Contd… Current Liabilities & provisions Liabilities 24701.77 26580.62 1878.85 7.61 Provisions 10065.17 14748.36 4683.19 46.53 Total Current Liabilities (F) 34766.94 41328.98 6562.04 18.87 Shareholders funds Share Capital (G) 2389.02 2389.02 0.00 0.00 Reserves & Surplus (H) 73192.01 80065.1 6873.09 9.39 Loan Funds Secured (I) 193.72 219.72 26.00 13.42 Unsecured (J) 10416.03 2296.51 (8119.52) (77.95) Deferred tax liability (K) 0 994.21 Total liabilities (F+G+H+I+J+K) 120957.7 127293.5 6335.82 5.24
  • 111. Comparative Balance Sheet of Marico Table 4.42 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 26046 33904 7858.00 30.17 Sundry Debtors 8627 11080 2453.00 28.43 Cash & bank balance 7528 9219 1691.00 22.46 Loans & advances 10609 12985 2376.00 22.40 Total CA (A) 52810 67188 14378.00 27.23 Fixed Assets (B) 25731 31110 5379.00 20.90 Investments ( C ) 1 1211 1210.00 121000.00 Goodwill on consolidation (D) 8424 8503 79.00 0.94 Deferred tax asset (E) 9817 6412 (3405.00) (34.68) Total Assets (A+B+C+D+E) 96783 114424 17641.00 18.23
  • 112. Contd… Current Liabilities & provisions Liabilities 25596.00 28027 2431.00 9.50 Provisions 3919 3551 (368.00) (9.39) Total Current Liabilities (F) 29515 31578 2063.00 6.99 Shareholders funds Share Capital (G) 6090 6090 0.00 0.00 Reserves & Surplus (H) 25372 39259 13887.00 54.73 Minority interest (I) 12 0 (12.00) (100.00) Loan Funds Secured (J) 13454 10751 (2703.00) (20.09) Unsecured (K) 22340 26746 4406.00 19.72 Total liabilities (F+G+H+I+J+K) 96783 114424 17641.00 18.23
  • 113. Comparative Balance Sheet of Nestle Table 4.43 2008 2009 Absolute Change Percentage (%) Currents Assets & loans Inventories 43491.17 49873.79 6382.62 14.68 Sundry Debtors 4559.33 6418.63 1859.30 40.78 cash & bank balance 19368.93 15558.63 (3810.30) (19.67) Loans & advances 12375.89 13804.87 1428.98 11.55 Total CA (A) 79795.32 85655.92 5860.60 7.34 Fixed Assets (B) 86216.11 97583.21 11367.10 13.18 Investments ( C ) 3489.92 20325.55 16835.63 482.41 Total Assets (A+B+C) 169501.4 203564.7 34063.33 20.10
  • 114. Contd... Current Liabilities & provisions Current liabilities 50746.71 58759.06 8012.35 15.79 Provisions 67731.57 83479.4 15747.83 23.25 Total Current Liabilities (D) 118478.3 142238.5 23760.18 20.05 Shareholders funds Share Capital (E) 9641.57 9641.57 0.00 0.00 Reserves & Surplus (F) 37693.4 48484.93 10791.53 28.63 Deferred tax liability/(assets) net (G) 3688.1 3199.72 (488.38) (13.24) Total liabilities (D+E+F+G) 169501.4 203564.7 34063.33 20.10
  • 115.
  • 116.
  • 117.
  • 118.